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A Major health problem worldwide, each year
5 15% of the population are affected with upper respiratory tract-           
infections 
3-5 million cases of severe illness 
250 000 – 500 000 deaths,  ,   
Pandemic and seasonal flu
Vaccination - the principal measure to prevent the disease and reduce 
the impact
Caused by influenza virus
8 segmented negative sense RNA genome
encode 11 proteins including 2 surface antigens: HA and NA              
Antigenic differences in HA and NA determine virus type (influenza A 
viruses) and lineage (influenza B viruses)
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Kaiser  et  al.,  Science,  Vol  312,  p.  380
http: www.who.int mediacentre actsheets s211 en index.html
FluMist®
FluMist®  (Influenza Virus Vaccine Live, Intranasal)        
Cold adapted live attenuated vaccine  ,     
Innovative  technology  (nasal  administration)
Antigen  sparing  (high  yield)
Durable mucosal and systemic immunity       
High  efficacy*
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*Belches  et  al.,  NEJM,  356  (7),  p.  685-696
Manufacture  of  FluMist® Influenza  Vaccines
6:2  reassortant 
ivacc neSelection 
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Blending  of  three  strains




      
Live,  Intranasal)
Old and New Influenza Vaccine
Production Technologies
Challenges with egg production platform
Egg stock vulnerability
Production capacity limited
Less defined biological starting material and significant       
operator intervention
Egg allergies
Advantages of cell culture-based production platform
Susceptibility to a broad spectrum of influenza virus strains
Better defined production substrate   







M di D b C i Kida n- ar y an ne ney 
(MDCK) cells
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Selection of Host Cell for 
Cell Culture Flu Vaccine Production    
Thirteen cell lines (9 mammalian and 4 avian host cells) 
were tested
MRC-5 WI-38 VERO FRhL-2 293 NIH 3T3 CHO MDCK and, , , , ,  , ,   
other human cell lines 
CEF, CEK, DF-1 and avian embryonic stem cell line
Only Vero and MDCK cells produced viruses >6.0 log10
TCID50/ml for FluMist strains
Only MDCK cells produced viruses with titer >7.0 log10
TCID50/ml for all types and families of seasonal strains 
tested
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Challenges Related with Use of MDCK cells 
for Vaccine Production
Original line of MDCK cells was non tumorigenic       
Some MDCK derivatives have been found to be highly 
tumorigenic 
Highly tumorigenic cell substrates have never been used 
to manufacture viral vaccines
Highly tumorigenic cell substrates pose significant 
regulatory challenges
Krause, VRBPAC 2005
Product Safety and Regulatory Concerns !
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MedImmune’s Approach
to Minimize Risk of MDCK Cells
Produced cell bank with low tumorigenic potential 
from biologically cloned cells
Extensive testing strategy developed Process 




Reduction of host cell DNA quantity
Reduction of host cell DNA size
Minimal exposure to animal derived components (ADCs)      




Tumorigenicity of live, intact cells
Oncogenicity of host cell DNA and lysate
Produced Low Tumorigenic Cell Bank
- Development of Serum-free MDCK Cells
Numerous in-house SFM formulations developed
Cells evaluated for several primary factors
Maintenance of cell line growth    
Potency (influenza virus yield)
Karyology
Tumorigenicity in athymic nude mouse model
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Tumorigenicity of 107 Uncloned MDCK
Cells in Adult Nude Mice
Treatment Group (n=10) Animals with Tumors
Tumor 
Formation Rate Note
MDCK Cells in Serum    
medium 0 0%
MDCK Cells in SFM A 6 60% tumors at injection site 
MDCK Cells in SFM B 0 0%
Negative Cell Control 0 0%
Positive Cell Control 10 100% tumors at injection site
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Produced Low Tumorigenic Cell Bank
- MDCK Cells Cloning
Began after development of SFM that maintained cell 
karyology and low potential tumorigenic nature of the 
ATCC MDCK cells
Initiated from a new vial of ATCC MDCK cells 
P f d i i i dier orme  n serum-conta n ng me a
Two rounds of limiting dilution cloning completed
Cl i iti ll l t d b d d ti itones n a y se ec e  ase  on pro uc v y
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< 7.6 7.6-7.9 8.0 8.1 8.2 8.3 8.4 8.5 8.6-8.8
Range of Virus Titer (log FFU/mL)
Range < 7.6 7.6-7.9 8.0 8.1 8.2 8.3 8.4 8.5 8.6-8.8 < 7.6 to 8.8
Clone No. 1014 105 38 35 16 11 6 1 2 1228
Percentage 82.6% 8.6% 3.1% 2.9% 1.3% 0.9% 0.5% 0.1% 0.2% 100%
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Not All High-Producing Clones in 





























Gradually reduced growth rate in SFM
No longer growing after 11 passages
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Eliminated from clone selection 


































































































Number of Passage in SFM105
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Tumorigenicity and Oncogenicity of 
Cloned MDCK Cells
Study Test Sample Animal with Tumors/ Location of Tumors
   
 Total Animals   
Tumorigenicity DPBS 2/33 lymph node, spleen, liver
adult nude mice Hela cells 38/41 site of injection
105 MDCK cells 1/44* spleen, liver, lung
101, 103,107 MDCK cells 0/132  
Tumorigenicity Hela cells 44/44 site of injection
NB nude mice 101, 103, 105, 107 MDCK cells 0/176
* tumors confirmed by histology examination, not sharing MDCK cell morphology, not located at SOI 
and not related with MDCK cells as verified by immunohistochemistry analysis
Test Samples Newborn Animals non-injected Saline MDCK cell lysate MDCK cell DNA
mice 1/25 0/45 0/45 n a
          
. .
hamsters 0/25 0/45 0/45 n.a.
rats 0/25 0/45 1/45* n.a.
mice 0/25 0/45 n.a. 1/45*
hamsters 0/25 0/45 n.a. 0/45
rats 0/25 1/45 n a 0/45
MDCK Cell Lysate 
Oncogenicity





A Flu Vaccine Manufacture Process 
without Extensive Process Development   
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Challenges Related with Annual Flu 
Vaccine Production 







































      
Short (often 1-3  weeks) Process Development Time
MedImmune’s Approach to Address 
Process Development Challenges  
Understand process parameters to all strains
Develop a true “platform  process”  capable  of  
production of all strains 
Conduct DOE and reduce pre-production PD 
time to approx. 2-4 weeks
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Time of Infection and Virus Yield 






Data  collected  using  shake  
flasks




















FFA  and  viable  cell  density  
























Error  bars  correspond  to  














Peak  titer  increases  with  the  time  of  infection  (e.g.,  4dps  vs  3dps)
.
0 1 2 3 4 5 6
Time of infection (days post seeding)
.
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irrespective  of  the  virus  input  at  the  time  of  infection
Trends  are  similar  among  different  sub-types 




Data  collected  using  shake  
flasks
Virus  titer  estimated  using  








  an   v a e  ce   ens y  
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Hours post infection (hpi)
.  
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Lower  virus  input  improves  virus  titer
Spread of Virus Productivity Using 
Phase I  Platform  Process
9.3































































































































































































































































































































































































Cold adapted vaccine strains
A/H
o
Improvement in Process  







































































































































































































































































































































































Average  productivity improvement  =  0.5  log10FFU/ml










Lowest  virus  titer  observed  7.9  log10FFU/ml (up  from  7.1  log10FFU/ml)
Reduced variability  in  yield,  increasing  process  robustness 
Fully Disposable Small Scale 
Platform Process
Cell inoculum expansion Virus production
T75 T225 RB RB 50L Single Use Bioreactor
Fully disposable process implemented in GMP Pilot Plant
20-21 days
No need for cleaning/validation with disposable culture vessels
Shortened timeline for implementation in clinical production
Quick turned-around between batches (in a few hours) making possible
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       ,   
to re-start production very rapidly.
Projected  Large-scale  
Manufacturing  Process 
Cell Factories
Vial Thaw
50 L Bi t





Cell  expansion Virus  production
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Theoretical Bulk Vaccine Dose Output
Number of Trivalent Doses (x10E+6)
Purification 
Yield (%)
     
Harvest Titer (FFU/mL)
 
8.0 8.1 8.2 8.3 8.4 8.5
15 58.7 73.9 93 117.1 147.4 185.6
20 78 2 98 5 124 156 1 196 5 247 4. . . . .
35 97.8 123.1 155 195.1 245.7 309.3
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Trivalent doses for 2x2000L bioreactors, 6 month campaign, 7.0 log10 FFU dose
Summary and Outlook
With a proprietary serum-free medium and through biological 
cloning, MedImmune has prepared a MDCK cell bank that is shown 
to be
Low in tumorigenicity and oncogenicity
High in virus productivity for both pandemic and seasonal influenza 
vaccine strains
By identifying and optimizing critical process parameters 
MedImmune has developed a flu vaccine platform manufacture 
process that is
highly productive for seasonal (H1N1, H3N2 and B) and pandemic 
(H5N1 H7N3 H9N2) virus strains with yield >8 log10FFU/mL, ,       
Used to complete Phase I GMP clinical production campaigns 
successfully in spite of a last minute change in H1N1 virus
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Phase II Process Development is on-going with focuses on process 
scale up, robustness and shorter development time
Posters #27 and #28 
Poster #27.   Development of a Cell Culture Production 
Platform for Cold-Adapted Live Attenuated Influenza 
Vaccine (CAIV) Strains of FluMist®: Effects and Interactions 
f M di C t T i d I fl Vio  e um omponen s, ryps n, an  n uenza rus 
Family/Type in Process Productivity
Poster #28 Development of a Cell Culture Production .       
Platform for Cold-Adapted live attenuated Influenza Vaccine 
(CAIV) strains of FluMist®: Accelerated Development of a 
Fully Disposable Phase I Clinical Manufacturing Process       
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